Targeting PPT1 might enable modulation of the protein palmitoylation/depalmitoylation balance, which has been implicated in AD and other neurodegenerative conditions, thus leading to the development of therapeutic strategies for treating neurodegenerative diseases.20 The gene discussed is PPT1; the disease is Alzheimer disease.